骨髓增生异常综合征中免疫表型异常造血干细胞:白血病进展的生物标志物
该研究分析68例MDS患者和53例对照的骨髓样本,区分造血干细胞与表达膜异常(CD7、CD11b、CD22、CD33、CD44、CD45RA、CD56、CD123、CD366或CD371)的免疫表型异常造血干细胞(IA-HSCs)。23/68例MDS骨髓存在IA-HSCs,其与造血 perturbed 及白血病进展风险增加相关(HR=25,95%CI:2.9-218),独立于常规风险因素。2年随访时,IA-HSCs存在预测白血病进展的敏感性和特异性分别为83%(95%CI:36-99%)和71%(95%CI:58-81%)。
要点
- 23/68例MDS骨髓可检测到免疫表型异常造血干细胞(IA-HSCs)。
- IA-HSCs存在与白血病进展风险增加相关,HR=25(95%CI:2.9-218)。
- 2年随访时IA-HSCs预测白血病进展的敏感性83%、特异性71%。
核心结论
- MDS骨髓中IA-HSCs的存在可预测白血病进展,提示其作为预后生物标志物的临床潜力。
研究设计与样本
- 分析68例MDS患者和53例对照的骨髓样本,通过免疫表型区分HSCs与表达膜异常的IA-HSCs。
- 在选定队列(n=10)中,将MDS骨髓异种移植入免疫缺陷小鼠观察。
主要发现
- 23/68例MDS骨髓含有IA-HSCs。
- IA-HSCs的存在与造血 perturbed(CD34+亚群不成比例扩增伴血细胞减少)相关。
- IA-HSCs的存在与白血病进展风险增加相关(HR=25,95%CI:2.9-218),独立于常规风险因素。
- 2年随访时,IA-HSCs存在预测白血病进展的敏感性为83%(95%CI:36-99%),特异性为71%(95%CI:58-81%)。
- 在选定队列(n=10)中,多数含IA-HSCs的MDS骨髓在异种移植后显示基因组复杂性和高人类原始细胞计数,与不含IA-HSCs的MDS骨髓形成对比。
关键数值与推荐
- IA-HSCs定义为表达膜异常(CD7、CD11b、CD22、CD33、CD44、CD45RA、CD56、CD123、CD366或CD371)的不成熟CD34+CD38-细胞。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myelodysplastic syndromes (MDS) comprise hematological disorders that originate from the neoplastic transformation of hematopoietic stem cells (HSCs). However, discrimination between HSCs and their neoplastic counterparts in MDS-derived bone marrows (MDS-BMs) remains challenging. We hypothesized that in MDS patients immature CD34+CD38- cells with aberrant expression of immunophenotypic markers reflect neoplastic stem cells and that their frequency predicts leukemic progression. We analyzed samples from 68 MDS patients and 53 controls and discriminated HSCs from immunophenotypic aberrant HSCs (IA-HSCs) expressing membrane aberrancies (CD7, CD11b, CD22, CD33, CD44, CD45RA, CD56, CD123, CD366 or CD371). One-third of the MDS-BMs (23/68) contained IA-HSCs. The presence of IA-HSCs correlated with perturbed hematopoiesis (disproportionally expanded CD34+ subsets beside cytopenias) and an increased hazard of leukemic progression (HR = 25, 95% CI: 2.9-218) that was independent of conventional risk factors. At 2 years follow-up, the sensitivity and specificity of presence of IA-HSCs for predicting leukemic progression was 83% (95% CI: 36-99%) and 71% (95% CI: 58-81%), respectively. In a selected cohort (n = 10), most MDS-BMs with IA-HSCs showed genomic complexity and high human blast counts following xenotransplantation into immunodeficient mice, contrasting MDS-BMs without IA-HSCs. This study demonstrates that the presence of IA-HSCs within MDS-BMs predicts leukemic progression, indicating the clinical potential of IA-HSCs as a prognostic biomarker.
引用
- van Spronsen MF, Hanekamp D, Westers TM, et al. Immunophenotypic aberrant hematopoietic stem cells in myelodysplastic syndromes: a biomarker for leukemic progression. Leukemia. 2023. PMID: 36792658. doi:10.1038/s41375-023-01811-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。